Thrombotic thrombocytopenic purpura (TTP) is a severe and potentially fatal syndrome increasingly reported shortly after allogeneic bone marrow transplantation. We report a 49-year-old patient who developed a recurrent and ultimately fatal form of TTP late after autotransplant for chronic myeloid leukemia. Keywords: bone marrow transplantation; thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation is increasingly reported. [1] [2] [3] [4] [5] [6] It is thought to result from high-dose chemotherapy and/or radiation therapy, which causes endothelial damage and RBC fragmentation.
Thrombotic thrombocytopenic purpura (TTP) after bone marrow transplantation is increasingly reported. [1] [2] [3] [4] [5] [6] It is thought to result from high-dose chemotherapy and/or radiation therapy, which causes endothelial damage and RBC fragmentation. 7 Clinical features of transplant-related TTP range from isolated asymptomatic hemolysis to life-threatening bleeding and neurological complications. 6 We report an unusual case of late, chronic relapsing fatal TTP occurring after an autotransplant for chronic myeloid leukemia (CML).
Case report
A 49-year-old female developed CML in December 1992. HLA typing found no HLA-identical relative. Her bone marrow was cryopreserved. Therapy with hydroxyurea and alpha interferon was begun. In February 1995, she received an autotransplant after conditioning cyclophosphamide (120 mg/kg) and total body radiation (6 Gy). There was bone marrow recovery on day 14, with no evidence of CML.
In February 1996, she developed sudden weakness of the left hand and dysphasia that lasted for 15 min, followed by chest pain. Physical examination was normal. An electrocardiogram showed anterior wall ischemia. Hemoglobin was 6.6 g/dl, WBC 4.6 × 10 locytes 0.08, myelocytes 0.06, promyelocytes 0.06, eosinophils 0.03, basophils 0.02, lymphocytes 0.40, monocytes 0.03). Platelets were 3 × 10 9 /l. The blood smear showed numerous schizocytes, helmet cells and markedly decreased platelets. Serum urea was 67 mg/dl (normal Ͻ50 mg/dl) creatinine 0.9 mg/dl (normal Ͻ1.2 mg/dl), LDH 1360 IU/l (normal Ͻ480 IU). Daily plasma exchange using cryosupernatant and intravenous plasma infusions was begun. Within 10 days, hemoglobin increased to 11 g/dl, platelets to 98 × 10 9 /l and the LDH decreased to 230 IU/l. The blood smear still showed mild microangiopathic hemolytic changes. One month later severe dysphasia, lasting for 1 h, recurred. The blood smear showed severe microangiopathic changes. Plasma infusions (12 units twice a day), were given. On the fifth day of therapy, severe cough and dyspnea appeared. WBC was 9.7 × 10 9 /l. There were no microangiopathic changes in the blood. A chest X-ray showed extensive bilateral lung infiltrates and a bronchoscopy showed alveolar bleeding. Biopsies of the lung were negative for fungus and Pneumocystis carinii.
Treatment
High-dose intravenous hydrocortisone (600 mg/day) led to a rapid, complete resolution of all clinical and radiologic findings. For the next 6 months, there were no complaints, and her hemoglobin and WBC were normal. The blood smear showed no microangiopathic changes. In September 1996, the patient developed transient paresia of the left hand and aphasia. The hemoglobin was 6.5 g/dl, WBC 8.9 × 10 9 /l with a normal differential and platelets 8 × 10 9 /l. The blood showed severe microangiopathic changes. Plasmapheresis and plasma infusions were promptly initiated without response. Five days later, she had a fatal cerebral hemorrhage. There was no post-mortem.
Discussion
We describe a 49-year-old female with CML who developed a chronic, relapsing fatal TTP 1 year after an autotransplant. The first and second episodes of TTP were relatively mild and responded rapidly to plasmapheresis and plasma infusions. For several months TTP was inac-tive, although microangiopathic changes persisted in the peripheral blood. The third and fatal event did not respond to plasma exchange using cryosupernatant.
Several factors are known to precede, and most probably cause, TTP after bone marrow transplant. For example, intensive chemotherapy, radiation graft-versus-host disease (GVHD) and cyclosporine. [1] [2] [3] [4] [5] [6] Endothelial damage is thought to be the main cause. 7 The first reported cases of TTP in transplant recipients included people with hemolytic-uremic syndrome (HUS) post transplant. 4, 5 Reported outcomes were variable. Rabinowe et al 4 described 16 people with HUS among 168 adults receiving transplants. None fulfilled the clinical and laboratory criteria for TTP. All 16 survived without sequelae. Juckett et al 5 summarized data from 10 patients who developed HUS late post transplant. Despite aggressive management, including plasma exchange, immunoglobulin administration and ex vivo staphylococcal protein A column plasma therapy, eight died. Recent reports confirm the severity of post-transplant TTP and the poor response to plasma exchange. Pettit and Clark 1 described several syndromes. A high-risk group included patients who presented with TTP early post transplant, who received cyclosporine and who had both renal and neurologic findings. A low mortality group included patients who presented late in their post-BMT course (120 days post BMT), and were not treated with cyclosporine. These observations were confirmed in a recent study that reviewed 172 cases of TTP/HUS reported to May 1996. 6 These authors identified three risk factors for mortality: (1) time to diagnosis; (2) use of cyclosporine; and (3) neurologic signs. It is often associated with CMV infection, hepatic veno-occlusive disease (VOD) or acute GVHD and has considerable mortality. The authors confirmed the mild course of late TTP, and favorable response to therapy. Our patient had late TTP after an autotransplant for CML. She did not receive cyclosporine and did not have CMV infection, VOD or GVHD. The recurrent and ultimately fatal course of the disease emphasizes the diversity of TTP, the limits of current classifications and the need for more effective therapy. 8 
